

NDA 20-766

Hoffmann-La Roche
Attention: Ms. Peggy Jack
Program Director
Drug Regulatory Affairs
340 Kingsland Street
Nutley, NJ 07110-1199

Dear Ms. Jack:

Please refer to your new drug application (NDA) dated November 26, 1996, received November 27, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Xenical (orlistat) Capsules, 120 mg.

We acknowledge receipt of your submissions dated May 12, 15, and 27, July 6, 15, 17, and 31, August 11, September 9, and October 7, 13, and 30, 1998; and January 6, 18, and 21(2), March 2, 11, 12, 22(2), 23, 24, 26, and 30, and April 1, 5, 7, and 23(2), 1999. Your submission of January 18, 1999, constituted a complete response to our May 12, 1998, action letter. The goal date for this application is July 19, 1999.

This new drug application provides for the use of Xenical (orlistat) Capsules for obesity management including weight loss and weight maintenance when used in conjunction with a reduced calorie diet. Xenical is also indicated to reduce the risk for weight regain after prior weight loss. Xenical is indicated for obese patients with an initial body mass index (BMI) ≥ 30 kg/m² or ≥ 27 kg/m² in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia).

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted April 23, 1999, patient package insert submitted April 23, 1999, and immediate container label submitted April 5, 1999). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material.

For administrative purposes, this submission should be designated "FPL for approved NDA 20-766." Approval of this submission by FDA is not required before the labeling is used.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

We remind you of your Phase 4 commitment specified in your submission dated April 23, 1999, to provide monthly updates of breast cancer diagnoses from the ongoing studies that were included in your January 18, 1999, submission. These updates will continue until these studies are completed.

As of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have not fulfilled the requirements of 21 CFR 314.55. We are deferring submission of your pediatric studies until 12/2/00. However, in the interim, please submit your pediatric drug development plans within 120 days from the date of this letter unless you believe a waiver is appropriate.

If you believe that this drug qualifies for a waiver of the pediatric study requirement, you should submit a request for a waiver with supporting information and documentation in accordance with the provisions of 21 CFR 314.55 within 60 days from the date of this letter. We will notify you within 120 days of receipt of your response whether a waiver is granted. If a waiver is not granted, we will ask you to submit your pediatric drug development plans within 120 days from the date of denial of the waiver.

Pediatric studies conducted under the terms of section 505A of the Federal Food, Drug, and Cosmetic Act may result in additional marketing exclusivity for certain products (pediatric exclusivity). You should refer to the *Guidance for Industry on Qualifying for Pediatric Exclusivity* (available on our web site at www.fda.gov/cder/pediatric) for details. If you wish to qualify for pediatric exclusivity, you should submit a "Proposed Pediatric Study Request" in addition to your plans for pediatric drug development described above. If you do not submit a Proposed Pediatric Study Request within 120 days from the date of this letter, we will presume that you are not interested in obtaining pediatric exclusivity [NOTE: You should still submit a pediatric drug development plan] and will notify you of the pediatric studies that are required under section 21 CFR 314.55. Please note that satisfaction of the requirements in 21 CFR 314.55 alone may not qualify you for pediatric exclusivity.

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Maureen Hess, MPH, RD, Regulatory Health Project Manager, at (301) 827-6411.

Sincerely,

James Bilstad, M.D.
Director
Office of Drug Evaluation II
Center for Drug Evaluation and Research